CoreRx, fast becoming a world-recognized leader in early drug contract development, has expanded its capabilities to include both a 17- and 34-cubic foot V-shell blender. This larger scale clinical manufacturing and support equipment will allow for a smooth transition from formulation development through clinical trials and into small commercial launches.
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include 15-cubic foot and 30-cubic foot V-shell blenders, a 43-station high speed tablet press, high speed encapsulation and a 40-inch solvent-capable coating pan. The additional equipment train will allow for increased clinical batch sizes in support of growing client demand. The additional equipment will allow CoreRx scientists to manufacture batch sizes of up to one million solid dosage units per day.
Common “First in Man” approaches vs. The Lost Art of Formulation Development
In today’s market, pharmaceutical and biotech companies are being asked to do more…with less. Diminishing resources, pipelines, competition, and increased regulatory hurdles are forcing us to rethink our strategy. We must work smarter, not harder.